{"id":27100,"date":"2026-07-20T10:03:08","date_gmt":"2026-07-20T08:03:08","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/il-digital-omnibus-cambia-lai-act-nel-pharma\/"},"modified":"2026-07-20T10:11:35","modified_gmt":"2026-07-20T08:11:35","slug":"il-digital-omnibus-cambia-lai-act-nel-pharma","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/il-digital-omnibus-cambia-lai-act-nel-pharma\/","title":{"rendered":"The Digital Omnibus Reshapes the AI Act for the Pharmaceutical Industry"},"content":{"rendered":"

For many observers, the Digital Omnibus<\/strong> signals a slowdown in the implementation of the AI Act. In reality, the message coming from Brussels is quite different: the objective is not to weaken the safeguards introduced by the European Artificial Intelligence Act, but to make its implementation more practical in sectors that are already subject to highly complex regulatory frameworks.<\/p>\n

This distinction is particularly relevant for the Life Sciences industry. Pharmaceuticals, medical devices and in vitro diagnostics operate within a regulatory ecosystem where quality, safety, risk management, cybersecurity and post-market surveillance requirements already coexist. The AI Act introduces an additional layer of governance that must be integrated into existing compliance systems without creating unnecessary duplication.<\/p>\n

This is precisely the rationale behind the Digital Omnibus: simplifying implementation while preserving the overall objectives of the regulation<\/strong>.<\/p>\n

Digital Omnibus<\/span><\/a><\/p>\n

A regulatory framework that must work together<\/h2>\n

The AI Act was designed as a horizontal regulation, applicable across all sectors of the economy.<\/p>\n

In the Life Sciences sector, however, artificial intelligence<\/strong> interacts with regulatory frameworks such as the Medical Device Regulation (MDR), the In Vitro Diagnostic Regulation (IVDR), Good Manufacturing Practices (GMP) and numerous international standards governing quality and risk management.<\/p>\n

Without proper coordination, companies could be required to repeat similar conformity assessments, generate duplicate technical documentation and navigate overlapping regulatory pathways. The Digital Omnibus seeks to address this challenge by harmonising these different regulatory layers without lowering existing safety standards.<\/p>\n

More time to prepare<\/h2>\n

One of the most significant elements of the Digital Omnibus is the revision of the implementation timeline for provisions concerning high-risk AI system<\/strong>s.<\/p>\n

The intention is not to delay the adoption of artificial intelligence, but to provide manufacturers, notified bodies and competent authorities with sufficient time to complete technical standards, guidance documents and conformity assessment procedures.<\/p>\n

For the Life Sciences sector, this additional time offers an opportunity to strengthen AI governance frameworks and integrate artificial intelligence into existing quality management systems.<\/p>\n

An impact that extends beyond medical devices<\/h2>\n

Much of the public discussion has focused on medical devices<\/strong>, since many AI-enabled software solutions fall within the AI Act’s high-risk category. However, the implications extend across the entire pharmaceutical value chain.<\/p>\n

Artificial intelligence is increasingly used in drug discovery, process development, predictive maintenance, automated visual inspection, document management, supply chain operations, pharmacovigilance and quality assurance.<\/p>\n

Not all these applications will qualify as high-risk AI systems under the AI Act. Nevertheless, they will all require robust governance<\/strong> capable of demonstrating data quality, human oversight, decision traceability and effective risk management.<\/p>\n

Dual compliance remains<\/h2>\n

For medical device manufacturers, the implementation timeline may change, but the underlying regulatory principle does not.<\/p>\n

AI-enabled medical devices will still need to comply simultaneously with sector-specific legislation and the requirements introduced by the AI Act.<\/p>\n

The real challenge will therefore be to establish integrated compliance pathways that minimise documentation overlap while improving the efficiency of conformity assessment activities. In this respect, the Digital Omnibus should primarily be viewed as a regulatory coordination initiative<\/strong>.<\/p>\n

An extra year that should not be wasted<\/h2>\n

Interpreting the revised timeline as an invitation to postpone preparations would likely be a mistake.<\/p>\n

Artificial intelligence is rapidly becoming an integral component of regulated industrial processes. Organisations that begin building AI governance frameworks<\/strong> today are likely to be better positioned once the regulatory framework becomes fully operational.<\/p>\n

Preparation means developing multidisciplinary expertise, defining organisational responsibilities, strengthening data quality, documenting AI models and establishing monitoring systems aligned with existing quality, cybersecurity and compliance processes.<\/p>\n

The real transformation is organisational<\/h2>\n

Much of the European debate has focused on the revised implementation schedule of the AI Act. For the Life Sciences industry, however, the more significant issue lies elsewhere.<\/p>\n

Artificial intelligence is no longer simply another technology to be introduced into business operations. It is becoming a permanent component of manufacturing, regulatory and decision-making infrastructures.<\/p>\n

Future compliance will depend not only on the characteristics of AI systems themselves, but also on organisations’ ability to integrate them into a coherent framework for risk management, quality assurance, cybersecurity and human oversight.<\/p>\n

From this perspective, the Digital Omnibus should not be interpreted as Europe stepping back from artificial intelligence regulation. Rather, it represents the transition from technology-specific regulation towards a more process-oriented governance model, where innovation and compliance must evolve together.<\/p>\n

Selected References<\/h2>\n